 Boronic Acids
"Boronic Acids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
| Descriptor ID |
D001897
|
| MeSH Number(s) |
D01.029.260.110 D01.132.285 D02.203.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Boronic Acids".
Below are MeSH descriptors whose meaning is more specific than "Boronic Acids".
This graph shows the total number of publications written about "Boronic Acids" by people in UAMS Profiles by year, and whether "Boronic Acids" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2014 | 1 | 3 | 4 | | 2013 | 6 | 7 | 13 | | 2012 | 3 | 9 | 12 | | 2011 | 4 | 3 | 7 | | 2010 | 3 | 6 | 9 | | 2009 | 4 | 3 | 7 | | 2008 | 6 | 3 | 9 | | 2007 | 4 | 4 | 8 | | 2006 | 2 | 0 | 2 | | 2005 | 1 | 2 | 3 | | 2004 | 1 | 1 | 2 | | 2002 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Boronic Acids" by people in Profiles over the past ten years.
-
Gunaganti N, Kharbanda A, Lakkaniga NR, Zhang L, Cooper R, Li HY, Frett B. Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chem Commun (Camb). 2018 Nov 15; 54(92):12954-12957.
-
Girnius SK, Lee S, Kambhampati S, Rose MG, Mohiuddin A, Houranieh A, Zimelman A, Grady T, Mehta P, Behler C, Hayes TG, Efebera YA, Prabhala RH, Han A, Yellapragada SV, Klein CE, Roodman GD, Lichtenstein A, Munshi NC. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. Br J Haematol. 2015 Apr; 169(1):36-43.
-
Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, Sharma S, Tricot G, Zhan F, Bearss DJ. Inhibition of Nek2 by small molecules affects proteasome activity. Biomed Res Int. 2014; 2014:273180.
-
Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE. Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1949-57.
-
Rabin N, Lai M, Pratt G, Morgan G, Snowden J, Bird J, Cook G, Bowcock S, Owen R, Yong K, Wechalaker A, Low E, Davies F. United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma. Int J Lab Hematol. 2014 Dec; 36(6):665-75.
-
Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, Davies FE, Morgan GJ, deSouza NM. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology. 2014 Jun; 271(3):785-94.
-
Zangari M, Berno T, Yang Y, Zeng M, Xu H, Pappas L, Tricot G, Kamalakar A, Yoon D, Suva LJ. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone. 2014 Apr; 61:39-43.
-
Zou D, An G, Zhu G, Wang J, Shi L, Meng H, Xu Y, Sui W, Deng S, Zhan F, Qiu L. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias. Biol Blood Marrow Transplant. 2014 Mar; 20(3):319-25.
-
An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014 Feb; 99(2):353-9.
-
Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. PLoS One. 2013; 8(10):e77608.
-
Morgan GJ. Transplants for the elderly in myeloma. Blood. 2013 Aug 22; 122(8):1332-4.
-
Bakhous A, Zhu H, Waheed S. Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid. Br J Haematol. 2013 Nov; 163(3):293.
-
Tao Y, Gao L, Wu X, Wang H, Yang G, Zhan F, Shi J. Down-regulation of 11ß-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukemia T cells against glucocorticoid-induced apoptosis. PLoS One. 2013; 8(6):e67067.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|